Astrana Health, Inc. (NASDAQ:ASTH) Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC reduced its position in Astrana Health, Inc. (NASDAQ:ASTH) by 49.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,127 shares of the company’s stock after selling 49,888 shares during the period. HighTower Advisors LLC’s holdings in Astrana Health were worth $1,581,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. Quarry LP purchased a new position in Astrana Health during the third quarter worth approximately $77,000. Quest Partners LLC purchased a new position in shares of Astrana Health during the 3rd quarter valued at approximately $133,000. KBC Group NV grew its stake in Astrana Health by 108.4% in the 4th quarter. KBC Group NV now owns 2,530 shares of the company’s stock valued at $80,000 after acquiring an additional 1,316 shares during the period. Paloma Partners Management Co purchased a new stake in Astrana Health in the 3rd quarter worth $220,000. Finally, Quantbot Technologies LP acquired a new position in Astrana Health during the third quarter worth $244,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

Astrana Health Stock Performance

Shares of Astrana Health stock opened at $31.89 on Tuesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. Astrana Health, Inc. has a 12 month low of $23.12 and a 12 month high of $63.20. The firm’s fifty day simple moving average is $34.01 and its 200-day simple moving average is $42.38. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of 24.53, a PEG ratio of 1.37 and a beta of 1.30.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). The business had revenue of $665.21 million during the quarter, compared to analysts’ expectations of $617.24 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. As a group, equities analysts forecast that Astrana Health, Inc. will post 1.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Truist Financial dropped their target price on shares of Astrana Health from $50.00 to $46.00 and set a “buy” rating on the stock in a research report on Tuesday, March 18th. Robert W. Baird dropped their target price on Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. Bank of America lowered their price objective on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Macquarie raised shares of Astrana Health to a “hold” rating in a research report on Monday, December 16th. Finally, Stifel Nicolaus dropped their price objective on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Astrana Health presently has an average rating of “Moderate Buy” and a consensus price target of $56.17.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.